Sagent Pharmaceuticals, Inc.

I'll research Sagent Pharmaceuticals to verify its profile.

Let me verify the litigation context and additional company details.

Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc. is a generic-injectable drugmaker headquartered in Schaumburg, Illinois (1901 N. Roselle Road). It was founded in 2006 by Jeffrey Yordon and was publicly traded on NASDAQ (ticker SGNT) from its 2011 IPO until 2016, when Japan's Nichi-Iko Pharmaceutical acquired it for roughly $736 million. Nichi-Iko subsequently divested the business to Penmetsa-controlled Ellimist Singapore Pte (reported around 2023), making Sagent a privately held operating subsidiary; PitchBook lists a 2025 acquisition by "Elliminist Singapore." At the end of 2015 it reported 440 full-time employees (114 in the U.S.) and 2015 sales of about $318 million.

Products / operations
Sagent develops, sources and markets generic prescription injectables for the U.S. hospital and clinic market. Its portfolio spans vials, prefilled syringes and premixed bags across therapeutic areas including anti-infectives, critical care, oncology and anaesthesia. Public drug databases list roughly 55+ approved products, with examples such as heparin, midazolam, esmolol, linezolid, piperacillin/tazobactam, cyclophosphamide, fludarabine and desmopressin. It markets products under its "PreventIV Measures" packaging and labeling program.

Patent-litigation posture
Sagent is an operating company that appears in the database solely as a defendant (0 plaintiff, 1 defendant), the classic profile of a generic manufacturer defending ANDA/Hatch-Waxman suits brought by brand owners rather than asserting patents itself. The single tracked matter was filed in the U.S. District Court for the District of New Jersey—not a plaintiff-friendly venue like the Eastern District of Texas.

Notable case
Helsinn Healthcare S.A. v. Sagent Pharmaceuticals, Inc. (D.N.J., 2:16-cv-00173, filed January 11, 2016) concerned Helsinn's ALOXI (palonosetron hydrochloride injection) patents (U.S. 7,947,724; 7,947,725; 7,960,424; 8,598,219; 8,729,094) and followed Sagent's Paragraph IV certifications on its ANDA. A related action (3:16-cv-00681) was filed in February 2016. The case terminated in July 2018 after a dispute over enforcement of a settlement and license agreement; the underlying Helsinn patents were also central to the parallel Helsinn v. Teva on-sale-bar litigation.

A note on uncertainty: ownership timelines and headcount figures come from press and aggregator sources that partly conflict, so current employee and revenue figures for the private company could not be independently verified.